Impedimed Limited · ASX:IPD
Impedimed — Investor Presentation (July 2014)
25 slides from Impedimed's investor presentation, Jul 21, 2014
Slide 1: Corporate Presentation
For personal use only Corporate Presentation ASX:IPD July 2014
Slide 2: Disclaimer
Disclaimer This presentation has been produced by ImpediMed Limited (“ImpediMed”) only and may contain forward-looking statements that are based on For personal use only management’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual res
Slide 3: Investment Summary
Investment Summary • Game changing technology platform For personal use only • Bioimpedance spectroscopy (BIS), accurately measures tissue composition and fluid status • Numerous medical and non-medical uses for our technology • Current and planned markets are compelling • $3 billion+ addressable ma
Slide 4: Recent Game Changing US Milestones
Recent Game Changing US Milestones For personal use only Unencumbered FDA clearance - June 2013 Reimbursement, CPT Category 1 Code awarded November 2013 (effective January 2015) Added 2 US Healthcare experienced board members - 2014 Post approval study, first enrollment - June 2014 Expanded use of o
Slide 5: The Need is Clear
The Need is Clear • Fluid imbalance can have significant clinical implications For personal use only • Fluid levels are incredibly predictive (actionable information) • Excess fluid can lead to chronic swelling, lymphoedema, left ventricular complications, etc. • Excess fluid is also indicative of h
Slide 6: Early Detection, Monitoring, and Treatment Improves Outcomes
Early Detection, Monitoring, and Treatment Improves Outcomes Condition Early Detection and Treatment For personal use only Lymphoedema - Approximately 1 in 3 Subclinical detection of cancer patients will develop lymphoedema and timely lymphoedema as a result of their intervention is able to reduce l
Slide 7: The Technology Gap
The Technology Gap • Current measurements tools are rudimentary and unreliable, or For personal use only prohibitively expensive, complicated and invasive • High-tech tools include CT scan, MRI, X-Ray absorptiometry, isotope dilution (lymphoscintigraphy) and perometry • Low-tech tools include tape m
Slide 8: Advantages of Bioimpedance Spectroscopy are Compelling
Advantages of Bioimpedance Spectroscopy are Compelling • Measurements using For personal use only bioimpedance at a single frequency is used to estimate body composition (limited Low Frequency High Frequency capabilities) • However, multiple frequencies are required to obtain complete information of
Slide 9: The Technology is "Game Changing"
The Technology is “Game Changing” • Informative – 256 frequency spectra provides For personal use only detailed measurements of muscle, fluid, and fat • Simple to Use – easy placement of electrodes • Fast – 5-10 mins to measure • Non-invasive – no dyes or radiation • Safe – no safety concerns report
Slide 10: The Market and Opportunity
The Market and Opportunity • Current and planned markets are significant and compelling For personal use only • Medical uses for lymphoedema , dialysis, obesity, muscle wasting, and venous insufficiency • FDA clearance is broad (cancer related lymphoedema) • Medicare reimbursement is scheduled for J
Slide 11: First Commercial Market - Lymphoedema
First Commercial Market - Lymphoedema • US addressable market $350+ million p.a. For personal use only • Lymphoedema affects ~1 in 3 cancer survivors • 900,000+ relevant new cancer cases p.a. • Lymphoedema is a progressive swelling that can occur following cancer treatment due to lymph nodes being r
Slide 12: The Importance of Early Detection
The Importance of Early Detection • Clinical practice is moving towards early detection and early intervention For personal use only • Current techniques used to assess lymphoedema cannot detect it before it is visibly apparent • L-Dex is able to detect minute changes in extracellular fluid (i.e. 35
Slide 13: Cancer Related Lymphoedema Market
Cancer Related Lymphoedema Market For personal use only Annual Cancer Incidences1 United States Breast Cancer (women) 232,000 Upper Limbs Pelvic Cancers2 630,000 Lower Limbs Melanoma (women & men) 77,000 Upper and Lower Limbs Total 939,000 Rest of World Market3 is more than 5 times the US Market 1.
Slide 14: Potential Revenue Model for L-Dex
Potential Revenue Model for L-Dex For personal use only Patient Testing Protocol ($30 per reading) Per Patient Year 1 30 Year 2 Year 3 Year 4 Total Readings 5 1-4 1-4 1-4 8 - 17 Revenue $150 $30 - $120 $30 - $120 $30 - $120 $240 - $510 Addressable US Lymphoedema Market over 4 Years Breast Cancer $55
Slide 15: The Targeted Launch Plan
The Targeted Launch Plan For personal use only Target Key Sites for Initial Marketing Launch • Targeting top 200 practices in key Medicare states: • High volume breast cancer centres • Established survivorship programs • Recognised KOL’s Sales and Marketing Organisation • Sales and marketing structu
Slide 16: L-Dex Incorporated into Clinical Guidelines
L-Dex Incorporated into Clinical Guidelines Key position statements on early detection of For personal use only lymphoedema - recommendations for BIS • Australasian Lymphology Association (ALA), Aus • National Lymphedema Network (NLN), US • National Accreditation Program for Breast Centers (NAPBC),
Slide 17: Third Party Trials Generating L-Dex Data
Third Party Trials Generating L-Dex Data United States For personal use only • 2 randomised controlled trials (n ~100 each site) being conducted at large teaching hospitals • Both investigating whether early intervention, identified with BIS, halts the progression of lymphoedema • Comparison between
Slide 18: ImpediMed's Post Market Approval Trial
ImpediMed’s Post Market Approval Trial • To help drive adoption ImpediMed is also sponsoring an international For personal use only study • Study commenced in June 2014 with Vanderbilt already recruiting patients. All trial sites expected to be live by year end • Large (n=1,100), multi-centre random
Slide 19: Looking Ahead
Looking Ahead For personal use only • New CPT code descriptors released October 2014 • CMS announces new Medicare payment rates November 2014 • CPT codes and new Medicare payment rates implemented January 2015 • Accelerating revenue in the US on the back of the CPT I code • Medicare reimbursement ex
Slide 20: Thank You
For personal use only 20 Thank You
Slide 21: Appendix
For personal use only 21 Appendix
Slide 22: Corporate Overview
Corporate Overview • ASX listed (October 2007) Share Price Performance – LTM For personal use only • Operations in US (San Diego) and Aus (Brisbane) • Transformed Board & Management in 2013 • 30 FTE staff • Market capitalisation ~$51M (~239M shares on Issue) • Cash on hand $10.81M (30 June 2014) • R
Slide 23: Financials
Financials (Preliminary and unaudited) FY2014 FY2013 % Change $000 $000 For personal use only Lymphoedema Revenue 1,594 1,189 34% Body Composition Revenue 892 728 23% Test & Measurement Revenue 1,035 816 27% Total Group Revenue 3,521 2,733 29% Operating Expenses 9,967 10,872 8% Operating Loss 7,935
Slide 24: Management Team Has Deep and Broad Commercialisation Experience
Management Team Has Deep and Broad Commercialisation Experience Rick Carreon • Joined July 2012 President and Chief Executive • 30+ years experience For personal use only Officer • Extensive experience in the medical device field and growth companies • Previously Vice President at Medtronic (10 year
Slide 25: Board of Directors
Board of Directors Cherrell Hirst AO • On Board since 2005 FTSE, MBBS, BEdSt, D.Univ • Appointed Non-Executive Chairman in Nov 2011 For personal use only (Hon), FAICD • Leading medical practitioner in breast cancer screening/diagnosis Non-Executive Chairman • Currently a Director of Tissue Therapies